Shares of the company rose nearly 6% in premarket trade as its quarterly revenue also beat Wall Street estimates, providing early signs of recovery on the back of a change in management.
The company had said on Monday it would delay its first-quarter filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in its consumer health and biomodalities unit, but would file preliminary results on Wednesday.
Catalent (NYSE:CTLT) has already delayed its other results several times this year to account for production snags at some of its plants.
The company recorded a net loss of $715 million for the quarter, which includes the goodwill impairment charge.
On an adjusted basis, Catalent recorded a net loss of $19 million, or 10 cents per share. Analysts had expected a loss of 14 cents per share, according to LSEG data.
Preliminary revenue for the first quarter fell 4%, to $982 million, but beat analysts’ average estimate of $939.14 million.
Source: Economy - investing.com
